Objectives: Primary familial brain calcification (PFBC) is a rare neurological disease often inherited as a dominant trait. Mutations in four genes (SLC20A2, PDGFB, PDGFRB, and XPR1) have been reported in patients with PFBC. Of these, point mutations or small deletions in SLC20A2 are most common. Thus far, only one large deletion covering entire SLC20A2 and several smaller, exonic deletions of SLC20A2 have been reported. The aim of this study was to identify the causative gene defect in a Finnish PFBC family with three affected patients.
| INTRODUCTION
Primary familial brain calcification (PFBC, also previously known as idiopathic basal ganglia calcification, IBGC, or Fahr's disease) is a rare neurological disorder with a variable phenotype. The disease onset is usually between 30 and 50 years, and the typical symptoms include both movement disorders (parkinsonism, dystonia, ataxia, chorea) and neuropsychiatric disturbances such as psychosis, dementia and frontal or subcortical cognitive dysfunction. The typical findings, bilateral and symmetric hydroxyapatite deposits, are seen in basal ganglia, dentate nuclei, and thalamus in patients with normal serum levels of calcium, phosphate, alkaline phosphatase, and parathyroid hormone. However, variation in the clinical manifestations is common even within families, and asymptomatic individuals with calcifications have been reported. [1] [2] [3] PFBC is often inherited as a dominant trait. The first causative gene, SLC20A2, was reported in 2012 by Wang et al. 2 Since the original report, many other studies have confirmed that mutations in this gene account for up to 40%-50% of PFBC. 4, 5 The other causative genes are PDGFRB on 5q32, 6 PDGFB on 22q13.1, 7 and XPR1 on 1q25.1.
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SLC20A2 codes for an inorganic phosphate (Pi) transporter PiT-2 that also functions as a retroviral receptor. Here, we report a novel heterozygous deletion covering the 5′ UTR and most likely the promoter region of SLC20A2 and extending up to FNTA. The mutation segregates with PFBC in a Finnish family with three affected subjects. To our knowledge, this is the first report of a Finnish family with PFBC and the first SLC20A2 mutation in the noncoding region.
| MATERIALS AND METHODS

| Subjects
We studied a PFBC family with three affected patients, the proband 41.75x (III:2). Sequences were aligned to GRCh37/hg19. Variant calling pipeline followed the GATK best practice guidelines. 
| Genetic methods
| RESULTS
Sanger sequencing ruled out coding and splice site mutations in (Table S1 , Fig. S1 ). The deletion was also visible in the SNP array data (subject II:5) with breakpoints at rs11780448 (chr 8: 42,325,328) and rs13248091
(chr8: 42,929,226 bp) (Fig. S2) . The unaffected subject III:2 did not have the deletion based on WGS (Table S1 , Fig. S1 ).
The deletion removes the noncoding exon 1, 5′ UTR region and the putative promoter region of SLC20A2 as well as the whole coding regions of six other genes (SMIM19, CHRNB3, CHRNA6, THAP1, RNF170, and HOOK3). The other deletion breakpoint is located between the second and third exons of FNTA.
To test whether the deletion segregates with PFBC in this family, we genotyped additional four unaffected family members on a SNP array.
The combination of WGS and SNP array data showed complete segregation of the deletion with the disease: The deletion was found in the two affected family members from whom DNA was available for testing and was absent in the five unaffected relatives ( Figure 1B, Fig. S2 ).
| DISCUSSION
Large deletions in causative genes for PFBC have been described in a few families. The first causative large copy number variant (CNV)
for PFBC was reported by Baker et al. in a Canadian family. 25 A partial deletion of PDGFB was subsequently described by Nicolas et al.
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Recently, smaller exonic deletions of SLC20A2 were reported in four patients. 31 We identified a ~578 kb deletion in a Finnish family with PFBC using both WGS and a SNP array. The exact breakpoints of the deletion could be identified from the whole-genome sequencing data. 25 the suggested disease mechanism was gain-of-function. Thus, the possible effects of deletion of one RNF170 allele are still unknown.
| CONCLUSIONS
Our results give further support for haploinsufficiency of SLC20A2 as a pathogenetic route in PFBC and suggest that deletion of regulatory regions of SLC20A2 is sufficient to cause the disease. The partial deletion of SLC20A2 described here demonstrates that copy number analysis is essential when screening for mutations in known causative genes in primary familial brain calcification. Ideally, CNV analysis should not be limited to coding regions as causative copy number variations may reside in regulatory regions of known disease-associated genes.
